RDUS Radius Health, Inc. Stock Quote

RDUS [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	1.00%	Shs Outstand	47.44M	Perf Week	3.66%
Market Cap	493.61M	Forward P/E	35.65	EPS next Y	0.29	Insider Trans	218.22%	Shs Float	47.35M	Perf Month	68.76%
Income	-72.70M	PEG	-	EPS next Q	-0.04	Inst Own	-	Short Float	17.69%	Perf Quarter	18.69%
Sales	216.90M	P/S	2.28	EPS this Y	36.80%	Inst Trans	5.06%	Short Ratio	7.23	Perf Half Y	55.49%
Book/sh	-5.61	P/B	-	EPS next Y	206.90%	ROA	-40.70%	Target Price	9.60	Perf Year	-42.58%
Cash/sh	-	P/C	-	EPS next 5Y	29.60%	ROE	29.40%	52W Range	4.97 - 23.00	Perf YTD	51.45%
Dividend	-	P/FCF	-	EPS past 5Y	18.90%	ROI	-60.60%	52W High	-54.43%	Beta	0.55
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	-	Gross Margin	91.10%	52W Low	110.87%	ATR	0.60
Employees	293	Current Ratio	1.80	Sales Q/Q	-23.30%	Oper. Margin	-25.20%	RSI (14)	70.90	Volatility	2.92% 7.82%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-14.90%	Profit Margin	-33.50%	Rel Volume	0.99	Prev Close	10.37
Shortable	Yes	LT Debt/Eq	-	Earnings	May 05 BMO	Payout	-	Avg Volume	1.16M	Price	10.48
Recom	3.30	SMA20	25.35%	SMA50	46.21%	SMA200	3.71%	Volume	1,125,589	Change	1.06%

Jun-08-22

Upgrade

BofA Securities

Underperform → Neutral

May-23-22

Initiated

SVB Leerink

Mkt Perform

Dec-10-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$18 → $7

Dec-10-21

Downgrade

Goldman

Buy → Neutral

$33 → $12

Dec-03-21

Initiated

BofA Securities

Underperform

$16

Mar-22-21

Resumed

Goldman

Buy

$33

Feb-24-21

Reiterated

H.C. Wainwright

Neutral

$22 → $25

Sep-29-20

Resumed

JP Morgan

Neutral

$23

Jul-08-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

$17

May-13-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$20

Apr-24-20

Initiated

Stifel

Hold

$20

Aug-29-19

Upgrade

Citigroup

Neutral → Buy

$24 → $40

May-30-19

Resumed

Citigroup

Neutral

May-29-19

Upgrade

Goldman

Neutral → Buy

Feb-14-19

Initiated

H.C. Wainwright

Neutral

$22

Mar-29-18

Initiated

Leerink Partners

Outperform

$53

Jan-29-18

Initiated

Morgan Stanley

Overweight

$57

Dec-06-17

Initiated

Citigroup

Neutral

$30

Oct-06-17

Resumed

Goldman

Neutral

Mar-24-17

Reiterated

H.C. Wainwright

Buy

$71 → $66

Jun-24-22 01:13PM	Radius (RDUS) to Go Private With $890M Deal, Shares Gain Zacks -6.73%
08:30AM	Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital Business Wire
Jun-23-22 01:33PM	Why Radius Health Climbed Today Motley Fool +21.66%
01:18PM	Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug Zacks
12:08PM	Bone Health Focused Radius Health Goes Private In $890M Deal Benzinga
09:15AM	Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital GlobeNewswire
Jun-22-22 06:48PM	Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant PR Newswire
06:24PM	Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant PR Newswire
06:24PM	Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant CNW Group
04:30PM	Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant GlobeNewswire
Jun-21-22 07:00AM	Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders Business Wire +9.02%
Jun-16-22 09:00AM	Rubric Capital Management Sends Letter to Radius Health Board of Directors Business Wire +17.10%
Jun-13-22 07:00AM	Velan-Repertoire Responds to Misleading Characterizations by the Radius Board Business Wire
Jun-08-22 08:00AM	Radius Health Expands Non-US Market Footprint for TYMLOS GlobeNewswire
Jun-07-22 07:00AM	Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting Business Wire +7.90%
Jun-06-22 11:07AM	Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
10:54AM	Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
10:54AM	Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting CNW Group
09:00AM	Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
07:30AM	Radius Files Definitive Proxy and Mails Letter to Stockholders GlobeNewswire
Jun-04-22 10:33AM	An Intrinsic Calculation For Radius Health, Inc. (NASDAQ:RDUS) Suggests It's 28% Undervalued Simply Wall St.
Jun-02-22 03:17PM	Radius (RDUS) to Stop Work on Abaloparatide Transdermal System Zacks
08:16AM	Radius to stop development of patch for osteoporosis drug MarketWatch
Jun-01-22 04:15PM	Radius Health Update on Abaloparatide Transdermal System GlobeNewswire
May-20-22 12:54PM	Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug Zacks +7.02%
09:46AM	Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer Benzinga
09:00AM	Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors GlobeNewswire
08:52AM	Do Options Traders Know Something About Radius Health (RDUS) Stock We Don't? Zacks
04:17AM	Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology PR Newswire
03:57AM	Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology CNW Group
May-19-22 05:00PM	Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology GlobeNewswire
May-06-22 01:30PM	Radius Health (RDUS) Q1 2022 Earnings Call Transcript Motley Fool
12:43PM	Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline Zacks
May-05-22 08:45AM	Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates Zacks -13.87%
07:30AM	Radius Health, Inc. First Quarter 2022 Results GlobeNewswire
06:47AM	The past five years for Radius Health (NASDAQ:RDUS) investors has not been profitable Simply Wall St.
Apr-28-22 03:02PM	Radius Health (RDUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-25-22 08:30AM	Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022 GlobeNewswire
Apr-05-22 08:00AM	Radius Provides Agenda for Todays R&D Webcast GlobeNewswire
Mar-16-22 08:30AM	Radius Health Announces Leadership Appointments GlobeNewswire
Mar-08-22 08:30AM	Radius Health Provides Business Update on Bone Health GlobeNewswire +5.60%
Mar-07-22 08:30AM	Wells Fargo Equity Research to Host Fireside Chat with Radius CEO GlobeNewswire
Mar-03-22 04:05PM	Radius to Host Neuroscience R&D Webcast April 5, 2022 GlobeNewswire
Mar-01-22 10:00AM	Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet Zacks
08:00AM	Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis GlobeNewswire
Feb-25-22 11:03AM	Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates Zacks
Feb-24-22 06:30PM	Radius Health (RDUS) Q4 2021 Earnings Call Transcript Motley Fool +17.77%
09:05AM	Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:30AM	Radius Health, Inc. Fourth Quarter & Full Year 2021 Results GlobeNewswire
Feb-17-22 03:02PM	Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-15-22 12:00PM	Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022 GlobeNewswire
Feb-07-22 01:17PM	Market Sentiment Around Loss-Making Radius Health, Inc. (NASDAQ:RDUS) Simply Wall St.
Jan-13-22 09:00AM	Radius Health Completes Business Adjustment GlobeNewswire
Jan-10-22 08:57AM	Are Options Traders Betting on a Big Move in Radius Health (RDUS) Stock? Zacks
Dec-23-21 10:41AM	FDA Approves Update On Radius Health's Tymlos label Benzinga
08:30AM	Radius Announces Update on TYMLOS® (abaloparatide) Label GlobeNewswire
Dec-20-21 08:32AM	Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors GlobeNewswire
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... GuruFocus.com -6.71%
Dec-09-21 09:13AM	Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS Zacks -5.12%
Dec-08-21 01:33PM	Why Radius Health Stock Is Getting Pummeled Today Motley Fool -44.30%
10:15AM	Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021 GlobeNewswire
09:00AM	Radius Health to Host Conference Call Today, Wednesday, December 8, 2021 GlobeNewswire
09:00AM	Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis GlobeNewswire
Nov-17-21 03:01AM	These 40 Mass. companies made the new Deloitte Fast 500 list American City Business Journals
Nov-11-21 08:30AM	Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference GlobeNewswire
Nov-09-21 09:08AM	Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines Zacks
Nov-08-21 07:00PM	Radius Health (RDUS) Q3 2021 Earnings Call Transcript Motley Fool -10.29%
09:15AM	Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates Zacks
08:00AM	Radius Health, Inc.: Third Quarter 2021 Results GlobeNewswire
Nov-01-21 03:01PM	Earnings Preview: Radius Health (RDUS) Q3 Earnings Expected to Decline Zacks
Oct-29-21 08:57AM	Hedge Funds Are Selling Radius Health Inc (RDUS) Insider Monkey
Oct-21-21 01:15PM	CORRECTING and REPLACING -- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021 GlobeNewswire +7.84%
10:14AM	Radius (RDUS) Up On Positive Data From Breast Cancer Study Zacks
Oct-20-21 03:00PM	Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021 GlobeNewswire +16.36%
12:18PM	Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump Benzinga
12:08PM	Why Radius Health Stock Is Exploding Higher Today Motley Fool
08:30AM	Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer GlobeNewswire
08:22AM	Radius Health Reports Positive Phase 3 Cancer Treatment Trial Results Investing.com
Oct-19-21 10:57AM	Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal Zacks
Oct-18-21 08:30AM	Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis GlobeNewswire +5.70%
Oct-04-21 08:45AM	3 Stocks Insiders Are Buying Benzinga
Sep-30-21 06:03AM	The Petri Dish: Ex-Moderna CMO joins RNA startup, MIT spinout raises $30M American City Business Journals
Sep-28-21 10:11AM	10 Best Healthcare Stocks Under $20 According to Michael Castors Sio Capital Insider Monkey
09:54AM	Radius Health (RDUS) Stock Jumps 7.1%: Will It Continue to Soar? Zacks
Sep-27-21 07:21AM	3 Stocks Insiders Are Buying Benzinga +7.13%
Sep-22-21 08:00AM	TYMLOS Label and Business Update GlobeNewswire
Aug-09-21 09:46AM	Loss-Making Radius Health, Inc. (NASDAQ:RDUS) Expected To Breakeven In The Medium-Term Simply Wall St.
Aug-07-21 09:01AM	Radius Health (RDUS) Q2 2021 Earnings Call Transcript Motley Fool
Aug-06-21 11:26AM	Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Aug-05-21 08:45AM	Radius Health (RDUS) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM	Radius Health, Inc.: Second Quarter and Year-to-Date Results GlobeNewswire
Jul-29-21 03:05PM	Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-27-21 08:00AM	Radius Health Business Update GlobeNewswire
Jul-23-21 11:12AM	CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study GlobeNewswire
Jul-22-21 09:00AM	Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study GlobeNewswire
Jul-20-21 05:11PM	Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021 GlobeNewswire
12:43AM	Is Radius Health Inc (RDUS) Going to Burn These Hedge Funds? Insider Monkey
Jun-02-21 08:15AM	Radius Health Business Update GlobeNewswire

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH TARGET N V	10% Owner	May 18	Buy	5.57	477,824	2,661,002	8,733,538	May 20 11:35 AM
BIOTECH TARGET N V	10% Owner	Jan 06	Buy	6.31	300,000	1,894,410	8,255,714	Jan 07 11:33 AM
BIOTECH TARGET N V	10% Owner	Jan 05	Buy	6.30	250,000	1,574,650	7,955,714	Jan 07 11:33 AM
Rubric Capital Management LP	10% Owner	Dec 16	Buy	7.07	146,685	1,037,752	6,959,305	Dec 16 05:32 PM
Rubric Capital Management LP	10% Owner	Dec 15	Buy	6.77	180,744	1,223,637	6,812,620	Dec 15 05:22 PM
Rubric Capital Management LP	10% Owner	Dec 14	Buy	6.81	94,103	640,936	6,631,876	Dec 15 05:22 PM
Rubric Capital Management LP	10% Owner	Dec 13	Buy	7.08	187,391	1,326,803	6,537,773	Dec 15 05:22 PM
Rubric Capital Management LP	10% Owner	Dec 10	Buy	7.17	768,171	5,511,627	6,350,382	Dec 10 06:01 PM
Rubric Capital Management LP	10% Owner	Dec 09	Buy	7.58	264,644	2,007,087	5,582,211	Dec 10 06:01 PM
Rubric Capital Management LP	10% Owner	Dec 08	Buy	8.02	560,691	4,497,078	5,317,567	Dec 10 06:01 PM
BIOTECH TARGET N V	10% Owner	Sep 29	Buy	12.95	100,000	1,294,500	7,705,714	Oct 01 10:34 AM
BIOTECH TARGET N V	10% Owner	Sep 22	Buy	12.28	150,000	1,841,280	7,605,714	Sep 24 11:58 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience